We have located links that may give you full text access.
Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer.
European Radiology 2018 May
OBJECTIVES: Using preoperative PET/CT, we evaluated the prognostic value of preoperative [18 F]FDG uptake ratio between various metastatic lesions and primary tumour in patients with advanced serous epithelial ovarian cancer (EOC).
METHODS: We retrospectively reviewed patients with International Federation of Gynecology and Obstetrics (FIGO) stage III, IV serous EOC who underwent preoperative [18 F]FDG PET/CT scans. Clinico-pathological variables and PET/CT parameters such as maximum standardized uptake value of the ovarian cancer (SUVovary ), pelvic or para-aortic LN (SUVLN ), peritoneal (SUVperit ) and distant extra-peritoneal (SUVdist ) metastatic lesions, and the metastatic lesion-to-ovarian cancer standardized uptake value ratio were assessed.
RESULTS: Clinico-pathological data were retrospectively reviewed for 97 eligible patients. The median progression-free survival (PFS) was 18 months (range, 6-90 months) and 59 (60.8 %) patients experienced recurrence. In multivariate regression analysis, older age (p = 0.035, hazard ratio (HR) 1.032, 95 % CI 1.002-1.062), and high SUVperit /SUVovary (p = 0.046, HR 1.755, 95 % CI 1.011-3.047) were independent risk factors of recurrence. Patient group categorized by SUVperit /SUVovary showed significant difference in PFS (Log-Rank test, p = 0.001).
CONCLUSIONS: In patients with advanced serous EOC, preoperative SUVperit /SUVovary measured by [18 F]FDG PET/CT provides significant incremental performance for prediction of recurrence.
KEY POINTS: • PET/CT data from advanced serous epithelial ovarian cancer patients were analysed. • Prognostic value of SUV ratio between metastatic and primary tumour was investigated. • SUV perit /SUV ovary provides incremental performance for prediction of recurrence.
METHODS: We retrospectively reviewed patients with International Federation of Gynecology and Obstetrics (FIGO) stage III, IV serous EOC who underwent preoperative [18 F]FDG PET/CT scans. Clinico-pathological variables and PET/CT parameters such as maximum standardized uptake value of the ovarian cancer (SUVovary ), pelvic or para-aortic LN (SUVLN ), peritoneal (SUVperit ) and distant extra-peritoneal (SUVdist ) metastatic lesions, and the metastatic lesion-to-ovarian cancer standardized uptake value ratio were assessed.
RESULTS: Clinico-pathological data were retrospectively reviewed for 97 eligible patients. The median progression-free survival (PFS) was 18 months (range, 6-90 months) and 59 (60.8 %) patients experienced recurrence. In multivariate regression analysis, older age (p = 0.035, hazard ratio (HR) 1.032, 95 % CI 1.002-1.062), and high SUVperit /SUVovary (p = 0.046, HR 1.755, 95 % CI 1.011-3.047) were independent risk factors of recurrence. Patient group categorized by SUVperit /SUVovary showed significant difference in PFS (Log-Rank test, p = 0.001).
CONCLUSIONS: In patients with advanced serous EOC, preoperative SUVperit /SUVovary measured by [18 F]FDG PET/CT provides significant incremental performance for prediction of recurrence.
KEY POINTS: • PET/CT data from advanced serous epithelial ovarian cancer patients were analysed. • Prognostic value of SUV ratio between metastatic and primary tumour was investigated. • SUV perit /SUV ovary provides incremental performance for prediction of recurrence.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app